Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.

Sini P, Gürtler U, Zahn SK, Baumann C, Rudolph D, Baumgartinger R, Strauss E, Haslinger C, Tontsch-Grunt U, Waizenegger IC, Solca F, Bader G, Zoephel A, Treu M, Reiser U, Garin-Chesa P, Boehmelt G, Kraut N, Quant J, Adolf GR.

Mol Cancer Ther. 2016 Oct;15(10):2388-2398. Epub 2016 Aug 5.

2.

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.

Sanderson MP, Apgar J, Garin-Chesa P, Hofmann MH, Kessler D, Quant J, Savchenko A, Schaaf O, Treu M, Tye H, Zahn SK, Zoephel A, Haaksma E, Adolf GR, Kraut N.

Mol Cancer Ther. 2015 Dec;14(12):2762-72. doi: 10.1158/1535-7163.MCT-15-0539. Epub 2015 Oct 5.

3.

Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase.

Peter S, Bultinck J, Myant K, Jaenicke LA, Walz S, Müller J, Gmachl M, Treu M, Boehmelt G, Ade CP, Schmitz W, Wiegering A, Otto C, Popov N, Sansom O, Kraut N, Eilers M.

EMBO Mol Med. 2014 Dec;6(12):1525-41. doi: 10.15252/emmm.201403927.

4.

Microwave-assisted parallel synthesis of fused heterocycles in a novel parallel multimode reactor.

Treu M, Karner T, Kousek R, Berger H, Mayer M, McConnell DB, Stadler A.

J Comb Chem. 2008 Nov-Dec;10(6):863-8. doi: 10.1021/cc800081b. Epub 2008 Sep 23.

PMID:
18808188

Supplemental Content

Loading ...
Support Center